# Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours

> **NCT00220168** · PHASE4 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 33 (actual)

## Conditions studied

- Upper Gastrointestinal Tumours

## Interventions

- **DRUG:** Irinotecan, Capecitabine

## Key facts

- **NCT ID:** NCT00220168
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2009-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220168, "Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00220168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*